| Toggle Summary
|
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
|
View HTML
|
| Toggle Summary
|
Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences' Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates
Management to host conference call today at 8:30 a.m. Eastern Time
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting
MIN-101 to be highlighted in oral presentation
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
|
View HTML
|
